These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15078136)

  • 21. [Cancer treatment by comprehensive regulation of anti-tumor immune network].
    Kawakami Y
    Nihon Rinsho; 2010 Jun; 68(6):1094-9. PubMed ID: 20535961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy.
    Foster AE; Gottlieb DJ; Marangolo M; Bartlett A; Li YC; Barton GW; Romagnoli JA; Bradstock KF
    J Hematother Stem Cell Res; 2003 Feb; 12(1):93-105. PubMed ID: 12662440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality and quantity: new strategies to improve immunotherapy of cancer.
    Krueger C; Schneck JP; Oelke M
    Trends Mol Med; 2004 May; 10(5):205-8. PubMed ID: 15121045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular immunotherapy with dendritic cells in cancer: current status.
    Nencioni A; Brossart P
    Stem Cells; 2004; 22(4):501-13. PubMed ID: 15277696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular immunotherapy of cancer: an overview and future directions.
    Tao Z; Li S; Ichim TE; Yang J; Riordan N; Yenugonda V; Babic I; Kesari S
    Immunotherapy; 2017 Jun; 9(7):589-606. PubMed ID: 28595516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LiveCount Assay: concomitant measurement of cytolytic activity and phenotypic characterisation of CD8(+) T-cells by flow cytometry.
    Devêvre E; Romero P; Mahnke YD
    J Immunol Methods; 2006 Apr; 311(1-2):31-46. PubMed ID: 16527300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic combination of murine bone marrow-derived dendritic cells loaded ex vivo with whole tumor lysate and systemic chemotherapy mediates antitumor immune responses in vivo.
    Salem ML; Nassef M; Gomaa S; Essa I
    Biomed Pharmacother; 2017 Sep; 93():286-295. PubMed ID: 28648976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs.
    Osada T; Morse MA; Lyerly HK; Clay TM
    Int Immunol; 2005 Sep; 17(9):1143-55. PubMed ID: 16027139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular immunotherapy: antigen recognition is just the beginning.
    Chen DS; Davis MM
    Springer Semin Immunopathol; 2005 Jun; 27(1):119-27. PubMed ID: 15834723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adoptive immunotherapy for cancer.
    Ruella M; Kalos M
    Immunol Rev; 2014 Jan; 257(1):14-38. PubMed ID: 24329787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human myeloid dendritic cells for cancer therapy: does maturation matter?
    Skalova K; Mollova K; Michalek J
    Vaccine; 2010 Jul; 28(32):5153-60. PubMed ID: 20665974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic immune niches for cancer immunotherapy.
    Weiden J; Tel J; Figdor CG
    Nat Rev Immunol; 2018 Mar; 18(3):212-219. PubMed ID: 28853444
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential advantages of CD1-restricted T cell immunotherapy in cancer.
    Consonni M; Dellabona P; Casorati G
    Mol Immunol; 2018 Nov; 103():200-208. PubMed ID: 30308433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic cells: still a promising tool for cancer immunotherapy.
    Aragoneses-Fenoll L; Corbí AL
    Clin Transl Oncol; 2007 Feb; 9(2):77-82. PubMed ID: 17329218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.
    Baxevanis CN; Voutsas IF; Tsitsilonis OE; Gritzapis AD; Sotiriadou R; Papamichail M
    J Immunol; 2000 Apr; 164(7):3902-12. PubMed ID: 10725753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of antigen-specific cytotoxic T lymphocytes using a leukemic plasmacytoid dendritic cell line as antigen presenting cells.
    Yamahira A; Narita M; Nakamura T; Watanabe N; Kaji M; Taniguchi T; Hashimoto S; Furukawa T; Toba K; Aizawa Y; Kuzushima K; Takahashi M
    Leuk Res; 2011 Jun; 35(6):793-9. PubMed ID: 21216464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rational combinations of in vivo cancer antigen priming and adoptive T-cell therapy mobilize immune and clinical responses in terminal cancers.
    Ruan QZ; Fu JQ; Wu XX; Huang LP; Ruan RS
    Cancer Immunol Immunother; 2018 Jun; 67(6):907-915. PubMed ID: 29511794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stable expression of a retrovirally transferred adhesion molecule in a human tumor-specific CTL clone. Perspectives for the ex vivo manipulation of effector cells used in adoptive immunotherapy.
    Cochlovius B; Zawadzki V; Perschl A; Zöller M
    Adv Exp Med Biol; 1998; 451():345-8. PubMed ID: 10026894
    [No Abstract]   [Full Text] [Related]  

  • 39. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
    Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
    Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Innate immune cells for immunotherapy of autoimmune and cancer disorders.
    Schäfer C; Ascui G; Ribeiro CH; López M; Prados-Rosales R; González PA; Bueno SM; Riedel CA; Baena A; Kalergis AM; Carreño LJ
    Int Rev Immunol; 2017 Nov; 36(6):315-337. PubMed ID: 28933579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.